2664
G.J. Hoover et al. / Biochimica et Biophysica Acta 1834 (2013) 2663–2671
Preliminary analysis of the primary sequence of AtGLYR1 revealed
2.2. Site-directed mutagenesis of AtGLYR1 active site
several sequence elements that are consistent with members of the
β-HAD (β-hydroxyacid dehydrogenase) protein family [6]. Identification
of the β-HAD family was originally based on similarities in hydroxyacid
substrate specificity, oxidative reaction mechanism and conserved
glycine-rich sequence elements [13]. The crystal structure of NADP-
dependent sheep 6-PGDH (6-phosphogluconate dehydrogenase) in the
presence of its substrate 6-phosphogluconate revealed 14 strictly
conserved amino acid residues with the potential to be catalytically
important [14] (PBD ID 1PGP), and sequence alignments between this
protein and NAD-dependent rat 3-HIBADH (3-hydroxyisobutyrate dehy-
drogenase) enabled identification of a conserved glycine-rich consensus
element that includes two residues from the 6-PGDH active site [13].
Directed mutagenesis demonstrated K173 as catalytically crucial and
N177 as catalytically important residues in 3-HIBADH. Subsequent
mutagenesis and modeling studies enabled identification of additional
amino acids as catalytically important residues at the 6-PGDH active
site [15–19]. Recently, the crystal structures for Thermus thermophilus
HB8 3-HIBADH [20] (PDB ID 2CVZ), as well as Salmonella typhimurium
LT2 TSAR (tartronate semialdehyde reductase) [21] (PDB ID 1VPD) and
NADPH-dependent Eubacterium barkeri 2-(hydroxymethyl)glutarate
dehydrogenase [22] (PDB ID 3CKY) became available. This information
indicated that TSAR and 2-(hydroxymethyl)glutarate dehydrogenase
are also members of the β-HAD family.
In the present paper, information about the β-HAD protein family
allowed us to identify catalytically important amino acid residues
for glyoxylate reduction in AtGLYR1 by characterization of the kinetic
and binding properties of mutant enzymes. Initially, we had hoped to
gain insights into the mechanistic importance of the residues in both
glyoxylate and SSA reduction; however, kinetic studies of the mutant
enzymes were not possible with SSA since the activities were too low.
We were also able to solve the crystal structure of AtGLYR1 in the
absence of substrate (apoprotein; PDB ID 3DOJ) to 2.1 Å by molecular
replacement using a previously unrecognized member of the β-HAD
family, cytokine-like nuclear factor. This allowed us to model the 3-D
structure of the protein with substrate and co-factor. Together, these
studies provided support for the importance of these residues and
established the basis for including AtGLYR1 in the β-HAD protein family.
The QuickChange site-directed mutagenesis kit (Stratagene) was
used to introduce S121A, K170A, K170R, K170E, K170H, N174A,
F231A, D239A, T95A mutations into AtGLYR1 expression plasmid
pET15b, using the appropriate primers (see Table S1 in the supplemen-
tal material). Mutated plasmids were sent to Genologics (University of
Guelph, Laboratory Services Branch, Guelph, ON, Canada) for sequenc-
ing (ABI PRISM Sequencer Model 377, PerkinElmer Life Sciences, Foster
City, CA, USA).
2.3. Analysis of recombinant protein stability
Purified recombinant proteins were separated by electrophoresis on
a 10% SDS-PAGE gel. The separated proteins were detected by immuno-
blot analysis on nitrocellulose membrane with anti-His monoclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:500 dilution.
Blots were developed using alkaline phosphatase-linked secondary
antibody at 1:10,000 dilution (goat anti-mouse AP-linked, Sigma, St.
Louis, MO) and the alkaline phosphate conjugate substrate kit (Biorad,
Hercules, CA).
The purified recombinant enzymes were analyzed by steady-state
Trp fluorescence emission scans using PTI QuantaMaster C-61 steady-
state fluorimeter (Photon Technology International, London, Ontario,
Canada). The temperature of the cuvette was maintained at 22 °C
with a circulating water bath. For emission scans, the excitation
wavelength was 290 nm and the emission was scanned from 305 to
400 nm with a scan rate of 1.0 nm/s. The excitation and emission wave-
lengths were set to 2 and 4 nm, respectively. The final concentrations of
the native enzyme, denatured native enzyme (using 5 M guanidine-
HCl) and the mutant proteins were 60 μg/mL. Each protein spectrum
was corrected for the buffer only spectrum and the corrected spectra
were normalized. The normalized corrected spectra of the native and
mutant enzymes were superimposed to assess differences in shape
and emission maxima.
2.4. Enzyme assays
Enzymatic activity of the purified native and mutant AtGLYR1
enzymes was measured continuously as the oxidation of NADPH using
the protocol described previously [7]. Briefly, the reaction mixture
consisted of 50 mM 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic
acid, pH 7.8, 10% sorbitol, NADPH, glyoxylate and purified recombinant
enzyme. Kinetics with glyoxylate as the varied substrate were
conducted at a fixed concentration of NADPH (50 μM); for each enzyme
the concentration of glyoxylate was varied to give five to six data points
both above and below the Km. When NADPH was varied, the fixed con-
centration of glyoxylate was typically 8–10 times the Km for glyoxylate;
the only exception was for the F231A mutant where the maximum
concentration of glyoxylate achievable was 2.5 times the Km. For each
enzyme, the concentration of enzyme used was determined to be within
the linear range (0.75–2500 nM). One unit of activity equals 1 μmol/min,
and all kinetic data were obtained from measurements of initial rate.
Measurements were obtained in triplicate at each concentration and typ-
ically three to four biological replicates were used. Kinetic data were fit to
the Michaelis–Menten equation using non-linear least-squares analysis
(SigmaPlot2000, version 6.1; Enzyme Kinetics Module, version 1.0; Systat
Software Inc., Point Richmond, CA). A fit was deemed acceptable if it ex-
hibited random residuals, passed the runs test and reached minimum
error in all fitting parameters. Kinetics of the native AtGLYR1 enzyme
with lithium β-hydroxypyruvate (Sigma, St. Louis, MO) as the varied sub-
strate were performed essentially as described above for glyoxylate with
fixed concentrations of NADPH (50 μM) and enzyme (25 nM). For native
AtGLYR2, kinetics using glyoxylate as a varied substrate were essentially
the same as for AtGLYR1 with the exception that enzyme concentration
was 25 nM.
2. Materials and methods
2.1. Expression and purification of recombinant AtGLYR1
Recombinant AtGLYR2 was produced by amplifying a truncated
AtGLYR2 (Gene ID 838342) cDNA sequence lacking the N-terminal 58
amino acids using primers 5′-GCATCATATGTCTACCAGAGATGAACTTG
GAAC-3′ and 5′-GCATGGATCCCTAAGCTTCTCGGGATTTTGC-3′, thereby
providing a NdeI restriction site on the forward primer and a BamHI site
on the reverse primer. The amplified PCR product was cloned into the
pET-15b expression vector using NdeI/BamHI (Novagen, EMD Biosciences
Inc., Madison, WI, USA) and sequenced (University of Guelph, Laboratory
Services Branch, Guelph, ON, Canada).
The recombinant AtGLYR1 and AtGLYR2 were expressed from
the isopropyl-β-D-thiogalactopyranoside-inducible pET15b plasmid in
Escherichia coli BL21 pLysS and purified as described previously [7].
Briefly, post induction (2 h) the BL21 cells were collected by centrifuga-
tion, frozen overnight at −20 °C, lysed with lysozyme (1 mg/mL) in
buffer (100 mM Tris, pH 8.0, 0.5 mM phenylmethylsulfonyl-fluoride,
1 μg/mL pepstatin A, 2 μg/mL leupeptin) and precipitated with 10% poly-
ethylene glycol 8000 overnight. The precipitate was resuspended in
equilibration buffer (50 mM Tris, pH 8.0, 0.5 M NaCl, 20 mM imidazole,
100 μM phenylmethylsulfonyl-fluoride) and loaded on a 4 mL HIS-
Select® Nickel Affinity Gel (Sigma) to purify the His6-tagged protein (as
per manufacturer's protocol). The purity of the eluted protein was veri-
fied by SDS-PAGE (coomassie stained and western blot) and its concen-
tration was determined with the Bradford assay [7].